US stock · figures in US dollars · scored on full-year results
Humana Humana Inc. Common Stock
Humana scores 39/100 on fundamentals: in the bottom 13% of 503 scored S&P 500 stocks. Its strongest area is Cash & Dividends (63/100); its weakest is Price Fairness (0/100). It carries 2 warning flags: Weak Spot, Limited Data.
- Carries a Weak Spot flag
- Carries a Limited Data flag
An expensively priced stock, but price fairness needs attention.
Nearby peers
Ranks #51 of 60 in Healthcare by score
One-Minute Summary
Why Humana scores 39
An expensively priced stock, but price fairness needs attention.
Business Strength
25Why 25?
No data: Quarterly Momentum
Show 3 charts
Net Profit & Equity, with ROE
Revenue & Net Profit, with Net Margin
Sales grew about 36.9% over 4 years: customers keep spending more with this company.
Profit fell about 48.6% from where it was 4 years ago: the boom has cooled off.
Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)
Sales grew about 26.2% over the last 5 quarters: customers keep spending more with this company.
The company made a loss in at least one of the last 5 quarters: the bars below zero are losses, not profits.
Financial Safety
50Why 50?
No data: Current Ratio
Show chart
Debt vs Equity, with D/E ratio
Borrowings grew about 22.2% over 4 years: watch this; rising debt adds pressure in bad times.
Cash & Dividends
63Why 63?
Show 3 charts
Operating vs Free Cash Flow
Cash keeps coming in, though unevenly: fine, but worth keeping an eye on.
Cash vs Total Debt
Dividends per Share, with Yield
Dividends per share have been maintained or raised: management shares the rewards with you.
Price FairnessLowest pillar
0Why 0?
Show chart
Share Price: Weekly Closes (not part of the score)
The share price is up about 50.6% over the past year.
Risk
63Why 63?
No data: Inventory vs Sales (4yr) · Quarterly Consistency
Sector peers
Humana (HUM) scores 39/100 (Weak) on Score Your Stock's educational fundamentals model: in the bottom 13% of 503 scored S&P 500 stocks.
Its strongest pillar is Cash & Dividends (63/100); its weakest is Price Fairness (0/100).
Humana ranks #51 of 60 scored Healthcare stocks on Score Your Stock.
Yes. Humana (HUM) has a dividend yield of 0.9%, from dividends with an ex-date in the last 12 months. It pays out 34% of its profit as dividends. Its Cash & Dividends pillar scores 63/100.
From Malaysia, open an account with a broker that offers US shares (many local and app-based brokers do), convert ringgit to US dollars, then buy HUM. US shares trade one share at a time, not in lots of 100. Check the currency conversion fee and US dividend tax (usually 30% withheld for Malaysians) before you buy.
The overall score pools every measure across 5 weighted pillars: Business Strength, Financial Safety, Cash & Dividends, Price Fairness, and Risk. It uses the same rules as our Bursa scores. For banks, Financial Safety checks nonaccrual (impaired) loans, loan loss coverage and the CET1 capital ratio, from the FDIC call report of the group's main bank. Full methodology and the default weights: https://scoreyourstock.com/how. This is an educational tool, not investment advice.
Humana (HUM) is a Healthcare company (Healthcare Plans). On Score Your Stock's fundamentals check, it scores 39/100, rated Weak. Its biggest strength is Cash & Dividends (63/100); its main watch-out is Price Fairness (0/100). Shares currently cost about 39 years of its current profit to buy (P/E 38.9×). It also pays back about 0.8% of the share price as dividends each year. Full breakdown and daily-updated score: https://scoreyourstock.com/stocks/us/hum-humana
Full Financial History
Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.
| Financial Year | Revenue | Net Profit | Operating Cash Flow | Free Cash Flow | CapEx | Cash | Total Debt | Short-Term Debt | Equity | Total Assets | Total Liabilities | Dividends | Return on Equity (ROE) | Net Profit Margin | Debt-to-Equity | Interest Coverage | Dividend Payout Ratio | Div yield | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | US$ 145.7b | US$ 1.3b | US$ 2.5b | US$ 1.9b | US$ -590.0m | US$ 6.9b | US$ 14.2b | US$ 2.3b | US$ 19.2b | US$ 57.2b | US$ 37.9b | - | 7% | 1% | 0.7× | 3.4× | 34% | - | - | - |
| 2025 | US$ 129.7b | US$ 1.2b | US$ 921.0m | US$ 375.0m | US$ -546.0m | US$ 4.2b | US$ 12.4b | US$ 0.0m | US$ 17.7b | US$ 48.9b | US$ 31.2b | US$ 354.0m | 7% | 1% | 0.7× | 3.5× | 36% | 1% | 26.7× | 1.8× |
| 2024 | US$ 117.8b | US$ 1.2b | US$ 3.0b | US$ 2.4b | US$ -575.0m | US$ 2.2b | US$ 11.7b | US$ 577.0m | US$ 16.4b | US$ 46.5b | US$ 30.0b | US$ 354.0m | 7% | 1% | 0.7× | 3.6× | 36% | 1% | 25.7× | 1.9× |
| 2023 | US$ 106.4b | US$ 2.5b | US$ 4.0b | US$ 3.0b | US$ -1.0b | US$ 4.7b | US$ 11.7b | US$ 1.4b | US$ 16.3b | US$ 47.1b | US$ 30.7b | US$ 354.0m | 15% | 2% | 0.7× | 7.9× | 17% | 1% | 21.8× | 3.3× |